{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:10:30Z","timestamp":1777612230685,"version":"3.51.4"},"reference-count":50,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.3201\/eid2502.180798","type":"journal-article","created":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T16:18:20Z","timestamp":1546791500000},"page":"205-211","source":"Crossref","is-referenced-by-count":14,"title":["International Biological Reference Preparations for Epidemic Infectious Diseases"],"prefix":"10.3201","volume":"25","author":[{"given":"Tommy","family":"Rampling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Horby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2502.180798-201901150744-R1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/fvl-2017-0003","article-title":"Developing biological standards for vaccine evaluation.","volume":"12","author":"Page","year":"2017","journal-title":"Future Virol"},{"key":"key-10.3201\/eid2502.180798-201901150744-R2","unstructured":"World Health Organization. Recommendations for the preparation, characterization and establishment of intenational and other biological reference standards. Geneva: The Organization; 2006."},{"key":"key-10.3201\/eid2502.180798-201901150744-R3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2017.0642","article-title":"Ehrlich and Von Behring.","volume":"317","author":"Ehrlich and Von Behring","year":"2017","journal-title":"JAMA"},{"key":"key-10.3201\/eid2502.180798-201901150744-R4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1136\/bmj.2.1765.931","article-title":"The antitoxin treatment of diphtheria: M.","volume":"2","author":"Roux at the Institut Pasteur","year":"1894","journal-title":"BMJ"},{"key":"key-10.3201\/eid2502.180798-201901150744-R5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000149583","article-title":"The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize.","volume":"82","author":"Bosch","year":"2008","journal-title":"Pharmacology"},{"key":"key-10.3201\/eid2502.180798-201901150744-R6","first-page":"11","article-title":"H.H. Dale and the London Centre for WHO standards\u2014some milestones of the early years.","volume":"100","author":"Bangham","year":"1999","journal-title":"Dev Biol Stand"},{"key":"key-10.3201\/eid2502.180798-201901150744-R7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/1045-1056(91)90030-N","article-title":"The international contribution to the standardization of biological substances. I. Biological standards and the League of Nations 1921-1946.","volume":"19","author":"Cockburn","year":"1991","journal-title":"Biologicals"},{"key":"key-10.3201\/eid2502.180798-201901150744-R8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0140-6736(16)31152-7","article-title":"The need for global R&D coordination for infectious diseases with epidemic potential.","volume":"388","author":"Kieny","year":"2016","journal-title":"Lancet"},{"key":"key-10.3201\/eid2502.180798-201901150744-R9","unstructured":"World Health Organization. A research and development blueprint for action to prevent epidemics [cited 2018 Nov 7]. https:\/\/www.who.int\/blueprint\/en"},{"key":"key-10.3201\/eid2502.180798-201901150744-R10","unstructured":"World Health Organization. Annual review of diseases prioritized under the research and development blueprint: informal consultation., 2017 [cited 2018 Nov 7]. https:\/\/www.who.int\/emergencies\/diseases\/2018prioritization-report.pdf"},{"key":"key-10.3201\/eid2502.180798-201901150744-R11","unstructured":"World Health Organization. List of blueprint priority diseases; 2018 [cited 2018 Nov 7]. https:\/\/www.who.int\/blueprint\/priority-diseases\/en"},{"key":"key-10.3201\/eid2502.180798-201901150744-R12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nm.4131","article-title":"A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation.","volume":"22","author":"Modjarrad","year":"2016","journal-title":"Nat Med"},{"key":"key-10.3201\/eid2502.180798-201901150744-R13","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1080\/21645515.2017.1306615","article-title":"Vaccines for epidemic infections and the role of CEPI.","volume":"13","author":"Plotkin","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.3201\/eid2502.180798-201901150744-R14","unstructured":"World Health Organization. WHO collaborative study to assess the suitability of an interim standard for antibodies to Ebola virus, 2015 [cited 2018 Nov 7]. http:\/\/apps.who.int\/iris\/handle\/10665\/197777"},{"key":"key-10.3201\/eid2502.180798-201901150744-R15","unstructured":"Wilkinson DE, Hassall M, Mattiuzzo G, Stone L, Atkinson E, Hockley J, WHO collaborative study to assess the suitability of the first international standard and the first international reference panel for antibodies to Ebola virus, 2017 [cited 2018 Nov 7]. https:\/\/www.who.int\/biologicals\/expert_committee\/BS2316_Anti-EBOV_Antibodies_WHO_1st_IS_and_WHO_1st_International_Ref_Panel.pdf"},{"key":"key-10.3201\/eid2502.180798-201901150744-R16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/21645515.2015.1032490","article-title":"Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccine.","volume":"11","author":"Li","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.3201\/eid2502.180798-201901150744-R17","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/S0140-6736(17)31224-2","article-title":"Diagnostic preparedness for infectious disease outbreaks.","volume":"390","author":"Perkins","year":"2017","journal-title":"Lancet"},{"key":"key-10.3201\/eid2502.180798-201901150744-R18","unstructured":"World Health Organization. International reference materials [cited 2018 Nov 7]. https:\/\/www.who.int\/bloodproducts\/ref_materials\/en"},{"key":"key-10.3201\/eid2502.180798-201901150744-R19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12275-017-7026-y","article-title":"The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic.","volume":"55","author":"Chan","year":"2017","journal-title":"J Microbiol"},{"key":"key-10.3201\/eid2502.180798-201901150744-R20","doi-asserted-by":"publisher","first-page":"e0004948","DOI":"10.1371\/journal.pntd.0004948","article-title":"Diagnostics in Ebola virus disease in resource-rich and resource-limited settings.","volume":"10","author":"Shorten","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid2502.180798-201901150744-R21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1128\/JCM.00279-16","article-title":"Zika virus: diagnostics for an emerging pandemic threat.","volume":"54","author":"Waggoner","year":"2016","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid2502.180798-201901150744-R22","article-title":"Vaccines against Ebola virus.","author":"Venkatraman","year":"2017","journal-title":"Vaccine"},{"key":"key-10.3201\/eid2502.180798-201901150744-R23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!).","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"key-10.3201\/eid2502.180798-201901150744-R24","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA.","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2502.180798-201901150744-R25","article-title":"Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.","author":"Tapia","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid2502.180798-201901150744-R26","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial.","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"key-10.3201\/eid2502.180798-201901150744-R27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"rVSV\u0394G-ZEBOV-GP Study Group. A recombinant vesicular stomatitis virus Ebola vaccine.","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2502.180798-201901150744-R28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"key-10.3201\/eid2502.180798-201901150744-R29","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/13543784.2016.1240785","article-title":"Monoclonal antibodies for the treatment of Ebola virus disease.","volume":"25","author":"Moekotte","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"key-10.3201\/eid2502.180798-201901150744-R30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease in Guinea.","volume":"374","author":"van Griensven","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2502.180798-201901150744-R31","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection.","volume":"375","author":"Davey","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2502.180798-201901150744-R32","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3389\/fmicb.2017.01469","article-title":"Advances in developing therapies to combat Zika virus: current knowledge and future perspectives.","volume":"8","author":"Munjal","year":"2017","journal-title":"Front Microbiol"},{"key":"key-10.3201\/eid2502.180798-201901150744-R33","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia.","volume":"22","author":"Arabi","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid2502.180798-201901150744-R34","article-title":"Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review.","author":"Mustafa","year":"2017","journal-title":"J Infect Public Health"},{"key":"key-10.3201\/eid2502.180798-201901150744-R35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jviromet.2014.07.028","article-title":"Development of a versatile and stable internal control system for RT-qPCR assays.","volume":"208","author":"Felder","year":"2014","journal-title":"J Virol Methods"},{"key":"key-10.3201\/eid2502.180798-201901150744-R36","doi-asserted-by":"publisher","first-page":"e0142751","DOI":"10.1371\/journal.pone.0142751","article-title":"Development of lentivirus-based reference materials for Ebola virus nucleic acid amplification technology-based assays.","volume":"10","author":"Mattiuzzo","year":"2015","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2502.180798-201901150744-R37","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1128\/JCM.36.12.3590-3594.1998","article-title":"Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards.","volume":"36","author":"Pasloske","year":"1998","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid2502.180798-201901150744-R38","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.vaccine.2016.11.083","article-title":"Comparison of platform technologies for assaying antibody to Ebola virus.","volume":"35","author":"Wilkinson","year":"2017","journal-title":"Vaccine"},{"key":"key-10.3201\/eid2502.180798-201901150744-R39","doi-asserted-by":"publisher","first-page":"24897","DOI":"10.1038\/srep24897","article-title":"Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle.","volume":"6","author":"Dye","year":"2016","journal-title":"Sci Rep"},{"key":"key-10.3201\/eid2502.180798-201901150744-R40","doi-asserted-by":"publisher","first-page":"e1002042","DOI":"10.1371\/journal.pmed.1002042","article-title":"Toward a common secure future: four global commissions in the wake of Ebola.","volume":"13","author":"Gostin","year":"2016","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid2502.180798-201901150744-R41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/jama.2011.960","article-title":"The WHO pandemic influenza preparedness framework: a milestone in global governance for health.","volume":"306","author":"Fidler","year":"2011","journal-title":"JAMA"},{"key":"key-10.3201\/eid2502.180798-201901150744-R42","doi-asserted-by":"publisher","first-page":"e1000247","DOI":"10.1371\/journal.pmed.1000247","article-title":"Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1.","volume":"7","author":"Fidler","year":"2010","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid2502.180798-201901150744-R43","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMp1603734","article-title":"The Zika challenge.","volume":"374","author":"Haug","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2502.180798-201901150744-R44","unstructured":"Cheng M, Satter R, Goodman J. Health officials want more Zika samples, data from Brazil. The Associated Press, 2016 [cited 2018 Nov 7]. https:\/\/www.businessinsider.com\/ap-health-officials-want-more-zika-samples-data-from-brazil-2016-2"},{"key":"key-10.3201\/eid2502.180798-201901150744-R45","unstructured":"Diversity SOTCOB. Nagoya protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the convention on biological diversity [cited 2018 Nov 7]. https:\/\/www.cbd.int\/abs\/doc\/protocol\/nagoya-protocol-en.pdf"},{"key":"key-10.3201\/eid2502.180798-201901150744-R46","unstructured":"Council of Europe. Convention for the protection of human rights and dignity of the human bing with regard to the application of biology and medicine: convention on human rights and biomedicine. Treaty no. 1641997 [cited 2018 Nov 7]. https:\/\/rm.coe.int\/168007cf98"},{"key":"key-10.3201\/eid2502.180798-201901150744-R47","unstructured":"Final report to the European Commission on the project Basic Ethical Principles in Bioethics and Biolaw, 1995\u20131998 Part B 1999 [cited 2018 Nov 7]. http:\/\/cometc.unibuc.ro\/reglementari\/Basic-Ethical-Principles.pdf"},{"key":"key-10.3201\/eid2502.180798-201901150744-R48","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/1469-0691.12709","article-title":"Negative impact of laws regarding biosecurity and bioterrorism on real diseases.","volume":"20","author":"Wurtz","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"key-10.3201\/eid2502.180798-201901150744-R49","doi-asserted-by":"publisher","first-page":"e1003105","DOI":"10.1371\/journal.ppat.1003105","article-title":"Biosafety Level-4 laboratories in Europe: opportunities for public health, diagnostics, and research.","volume":"9","author":"Nisii","year":"2013","journal-title":"PLoS Pathog"},{"key":"key-10.3201\/eid2502.180798-201901150744-R50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2807\/1560-7917.ES.2018.23.19.17-00404","article-title":"Status, quality and specific needs of Ebola virus diagnostic capacity and capability in laboratories of the two European preparedness laboratory networks EMERGE and EVD-LabNet.","volume":"23","author":"Reusken","year":"2018","journal-title":"Euro Surveill"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/25\/2\/18-0798_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:27:17Z","timestamp":1732987637000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/25\/2\/18-0798_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2502.180798","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}